Promis Neuroscie Stock Price, News & Analysis

ProMIS Neurosciences (PMN) reported Q1 2025 financial results and significant progress in its clinical programs. The company's lead program, PMN310 for Alzheimer's disease, completed enrollment of its first cohort in the PRECISE-AD trial. The trial will evaluate multiple doses (5, 10, 20 mg/kg) across 128 patients at 22 U.S. sites. Six-month interim results are expected in 1H 2026, with topline results by end-2026. The company's cash position stood at $8.4M as of March 31, 2025, down from $13.3M in December 2024. Q1 2025 saw increased R&D expenses of $5.5M (vs $2.1M in Q1 2024) due to clinical trial costs. Net loss widened to $7.3M (vs $3.6M in Q1 2024). PMN310 targets toxic amyloid-beta oligomers and potentially offers improved safety by avoiding ARIA (Amyloid-Related Imaging Abnormalities), a serious concern with existing therapies. The company also advanced its ALS program (PMN267) and synucleinopathies vaccine program (PMN440) with promising preclinical data.

ProMIS Neurosciences (Nasdaq: PMN) reported its 2024 financial results and key developments. The company successfully initiated a 100-patient Phase 1b clinical trial for PMN310, their lead antibody candidate for Alzheimer's disease. The PRECISE-AD trial is currently enrolling and dosing patients across 22 US sites, with interim results expected in 1H 2026 and topline results by end of 2026.

Financial highlights include cash position of $13.3 million as of December 31, 2024, and completion of a PIPE financing providing $30.3 million upfront with potential for additional $92.4 million from warrant exercises. The company reported net income of $2.8 million for 2024, primarily due to a $22.6 million gain from warrant liability changes. R&D expenses increased to $10.6 million, while G&A expenses slightly decreased to $6.2 million.

The company expanded its IP portfolio with 23 newly granted patents, including 17 for PMN310. They also advanced programs in ALS and Parkinson's disease, identifying PMN440 as a lead vaccine candidate for multiple synucleopathies.

ProMIS Neurosciences (Nasdaq: PMN) announced plans to present preclinical data at the 2025 AD/PD International Conference in Vienna. The company will showcase three key presentations focusing on their platform-derived antibodies and vaccines for neurodegenerative diseases.

The presentations include: (1) A study on Alzheimer's vaccine design showing that immunization with peptide 301 produced maximal reactivity against AD brain oligomers; (2) Research on alpha-synuclein vaccine optimization for treating conditions like Parkinson's disease, demonstrating high-affinity antibodies with selectivity for pathogenic ASyn; and (3) Development of selective antibodies targeting misfolded TDP-43 for treating ALS, frontotemporal dementia, and AD.

The virtual oral presentations will be available on demand starting April 1, 2025, at 7:00am CET.

ProMIS Neurosciences (Nasdaq: PMN) will present preclinical data on computationally-derived vaccines for neurodegenerative diseases at the American Academy of Neurology Annual Meeting (April 5-9, 2025) in San Diego.

The company will showcase two key presentations: First, a study on Alzheimer's vaccine optimization showing that immunization with peptide 301 produced maximal reactivity against AD brain oligomers. Second, research on a vaccine for synucleinopathies demonstrating that vaccination with conformational B cell epitopes generated high-affinity antibodies selective for pathogenic alpha-synuclein.

The research focuses on targeting toxic misfolded proteins in conditions like Alzheimer's disease, amyotrophic lateral sclerosis, and multiple system atrophy. The company's approach aims to develop vaccines that specifically target toxic amyloid-beta oligomers for AD and pathogenic species of alpha-synuclein for MSA and other synucleinopathies.

ProMIS Neurosciences (Nasdaq: PMN), a clinical-stage biotechnology company specializing in antibody therapeutics for neurodegenerative diseases, has announced its participation in the 37th Annual Roth Conference. Neil Warma, the company's CEO, will engage in a fireside chat on March 18, 2025 at 8:00 a.m. PT in Dana Point, CA.

The company focuses on developing treatments targeting toxic misfolded proteins in three main areas:

• Alzheimer's disease (AD)
• Amyotrophic lateral sclerosis (ALS)
• Multiple system atrophy (MSA)

A live webcast of the presentation will be available on the Events page of ProMIS Neurosciences' website and will remain accessible for at least 30 days after the event.

ProMIS Neurosciences has begun dosing multiple patients in its Phase 1b PRECISE-AD trial for Alzheimer's disease, marking a significant milestone for the company. The trial is evaluating PMN310, a humanized monoclonal antibody designed to selectively target toxic amyloid-beta oligomers while avoiding binding to monomers and amyloid plaques.

This selective targeting approach potentially differentiates PMN310 from other Alzheimer's treatments on the market or in development, with the goal of delivering a more effective and well-tolerated therapy. The rapid enrollment underscores the urgent unmet need for better Alzheimer's treatments.

The company expects six-month interim results in the first half of 2026, with topline results anticipated in the second half of 2026. Trial investigators highlighted that current Alzheimer's treatments offer only modest efficacy and often come with significant side effects like ARIA.

ProMIS Neurosciences (Nasdaq: PMN), a clinical-stage biotechnology company, has announced its participation in the upcoming Guggenheim Securities SMID Cap Biotech Conference. The company's CEO, Neil Warma, will engage in a fireside chat on Wednesday, February 5, 2025, at 1:30 p.m. ET in New York.

ProMIS specializes in developing antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, including Alzheimer's disease, ALS, and multiple system atrophy. The fireside chat will be accessible via live webcast through the Events page on the company's website and will remain available for at least 30 days after the event.

ProMIS Neurosciences (Nasdaq: PMN) shared key achievements from 2024 and outlined plans for 2025 in a shareholder letter. The company successfully completed its Phase 1a clinical trial for PMN310, their lead Alzheimer's disease (AD) treatment, which demonstrated good tolerability and potential target engagement. In July 2024, ProMIS secured up to $122.7 million in financing from healthcare specialty funds to support their ongoing Phase 1b PRECISE-AD clinical trial.

The Phase 1b trial aims to enroll approximately 100 AD patients, with interim data expected in H1 2026 and topline results by year-end 2026. PMN310 targets toxic oligomers while sparing plaque, potentially offering improved safety by reducing ARIA risk. The company's pipeline includes additional candidates PMN267 for ALS/FTD, PMN442 for MSA/Parkinson's, and vaccine candidates PMN400 and PMN311, some of which could enter clinical trials within 12-18 months.

ProMIS Neurosciences has initiated its Phase 1b clinical trial (PRECISE-AD) evaluating PMN310, a humanized IgG1 antibody, for Alzheimer's disease. The trial will assess safety, tolerability, and pharmacokinetics over 12 months in 100 patients with mild cognitive impairment or early AD.

PMN310 is engineered to selectively target toxic oligomers of amyloid-beta while avoiding plaque deposits, potentially reducing the risk of amyloid-related imaging abnormalities (ARIA), a common side effect in existing therapies. The study will be conducted across 22 U.S. sites, with patients receiving monthly doses at three levels (5, 10, 20 mg/kg) or placebo.

Results from the completed Phase 1a study in healthy volunteers showed favorable safety and tolerability. The company expects to share interim data in the first half of 2026.